<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02948101</url>
  </required_header>
  <id_info>
    <org_study_id>2016-0053</org_study_id>
    <secondary_id>NCI-2016-01928</secondary_id>
    <nct_id>NCT02948101</nct_id>
  </id_info>
  <brief_title>Pre-Conditioning Effects of Anti-Macrophage Therapy Using PD 0360324 in Recurrent Platinum-Resistant Epithelial Ovarian Cancer</brief_title>
  <official_title>Pilot Study of the Pre-Conditioning Effects of Anti-Macrophage Therapy Using PD 0360324 in Recurrent Platinum-Resistant Epithelial Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn about the effects of PD 0360324 on
      participant's immune system in participant's with epithelial ovarian, Fallopian tube, or
      primary peritoneal cancer and who have agreed to participate on Protocol PA13-0291. As part
      of this study, participant will also receive a type of standard chemotherapy called
      cyclophosphamide.

      The safety of PD 0360324 and cyclophosphamide will also be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Drug Administration:

      Cycle 1 is 42 days. Cycles 2 and beyond are 28 days.

      If participant is found to be eligible to take part in this study, they will receive PD
      0360324 by vein over about 30 minutes on Days 1, 8, 15, and 22 of Cycle 1. These are the only
      4 doses that participant will receive of the study drug.

      Starting at Cycle 2, participant will take 1 cyclophosphamide capsule by mouth at the same
      time every day in the morning with about 1 cup (8 ounces) of water. The capsules should not
      be chewed, crushed, or cut.

      If participant forgets to take a dose, they may take it within 12 hours after the usual
      dosing time. If participant vomits within 30 minutes after taking a dose, they should take
      the dose again.

      If it has been more than 12 hours since forgetting to take dose or if participant vomits and
      it has been more than 30 minutes since their dose, they should not take another dose.
      Participant should wait and take their next dose as scheduled.

      Length of Study:

      Participant may receive up to 4 doses of PD 0360324. Participant may continue to receive
      cyclophosphamide for as long as the study doctor thinks it is in their best interest.
      Participant will no longer be able to take the study drugs if the disease gets worse, if
      intolerable side effects occur, or if they are unable to follow study directions.

      Participation on the study will be over after participant has completed the follow-up visits
      (described below).

      Study Visits:

      On Day 1 of Cycle 1:

        -  Participant will have a physical exam.

        -  Blood (about 3 tablespoons) will be drawn within 6 hours before participant's dose of
           study drugs for routine, biomarker, pharmacokinetic (PK), and pharmacodynamic (PD)
           testing. PK testing measures the amount of study drug in the body at different time
           points. PD testing measures how the level of study drug in participant's body may affect
           the disease. If participant can become pregnant, this blood will also be used for a
           pregnancy test.

        -  Participant will have an EKG.

      On Days 8, 15, and 22 of Cycle 1:

        -  Participant will have a physical exam.

        -  Blood (about 3 tablespoons) will be drawn within 6 hours before participant's dose of
           study drugs for routine, PK, and PD testing. On Day 8 only, this blood sample will also
           be used for immune system testing.

        -  Participant will have an EKG.

      Between Days 29 and 36 of Cycle 1:

        -  Blood (about 3 tablespoons) will be drawn for immune system, PK, and PD testing.

        -  Participant will have an MRI or CT scan.

        -  Participant will have a tumor biopsy for immune system testing.

      On Day 1 of Cycles 2 and beyond:

        -  Participant will have a physical exam.

        -  Blood (about 3 tablespoons) will be drawn for routine and biomarker testing.

        -  During Cycle 3 only, blood (about 2 tablespoons) will be drawn for PK and PD testing.

        -  During Cycle 2, participant will have an EKG. After Cycle 2, participant will have an
           EKG only if the doctor thinks it is needed.

        -  If participant can become pregnant and the doctor thinks it is needed, part of the above
           blood sample will also be used for a pregnancy test.

      At Day 1 of Cycle 4 and every even-numbered cycle after that (Cycles 6, 8, 10, and so on),
      participant will have an MRI or CT scan.

      End-of-Dosing Visit:

      About 7 days after participant's last study drug dose:

        -  Participant will have a physical exam.

        -  Blood (about 3 tablespoons) will be drawn for routine, immune system, biomarker, PK, and
           PD testing.

        -  Participant will have an EKG.

        -  Participant will have an MRI or CT scan.

        -  If the study doctor thinks it is possible and if participant did not receive all doses
           of PD 0360324, they will have a core tumor biopsy for biomarker and immune system
           testing.

      Follow-Up Visits:

      About 30 and 90 days after your last dose of study drugs:

        -  Participant will have a physical exam.

        -  Blood (about 3 tablespoons) will be drawn for routine and biomarker testing.

        -  Participant will have an EKG.

        -  Participant will have an MRI or CT scan.

      This is an investigational study. PD 0360324 is not FDA approved or commercially available.
      It is currently being used for research purposes only. Cyclophosphamide is FDA approved and
      commercially available for the treatment of many types of cancer, including ovarian cancer.

      The study doctor can tell participant how the study drugs are designed to work.

      Up to 15 participants will be enrolled in this study. All will take part at MD Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2018</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of PD 0360324 Followed by Cyclophosphamide in Participants with Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancers</measure>
    <time_frame>Baseline to 4th week of Cyclophosphamide administration</time_frame>
    <description>Extreme toxicity (TOX) defined as any grade 3 or higher adverse event or any grade of ocular edema that is possibly, probably, or definitely related to any therapy received on this protocol and occurs between the first dose of PD 0360324 and the end of the 4th week of cyclophosphamide.
Adverse events graded according to the NCI CTCAE v4.03.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Density of Cluster of Differentiation 8 (CD8+) T cells in Tumor Biopsies Before and After PD 0360324</measure>
    <time_frame>Baseline, and Days 1, 8, 15, 22, of Cycle 1</time_frame>
    <description>CD8+ T cells as the primary endpoint reported descriptively at each time point. Continuous measures presented with nonparametric methods such as median and IQR or boxplots, while correlations (Pearson's or Spearman's as indicated) calculated with other continuous measures.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) Associated With Low Dose Oral Cyclophosphamide After PD 0360324 Treatment</measure>
    <time_frame>30 and 90 days after last dose of study drugs</time_frame>
    <description>PFS presented with a Kaplan-Meier curve as long as more than 10 patients are entered on the trial. Assessment of disease per (RECIST v1.1)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Malignant Neoplasm of Female Genital Organs</condition>
  <arm_group>
    <arm_group_label>PD 0360324 + Cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1 is 42 days. Cycles 2 and beyond are 28 days.
Participants receive PD 0360324 by vein over about 30 minutes on Days 1, 8, 15, and 22 of Cycle 1. Participants only receive 4 doses.
Starting at Cycle 2, participants take 1 Cyclophosphamide capsule by mouth at the same time every day in the morning.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PD 0360324</intervention_name>
    <description>50 mg by vein on Days 1, 8, 15, and 22 of Cycle 1. Participants only receive 4 doses.</description>
    <arm_group_label>PD 0360324 + Cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Starting at Cycle 2, participants take 1 Cyclophosphamide 50 mg capsule by mouth at the same time every day in the morning until progression.</description>
    <arm_group_label>PD 0360324 + Cyclophosphamide</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent.

          2. Age &gt;/= 18 years at time of study entry.

          3. Histology showing recurrent high grade epithelial ovarian, peritoneal, or fallopian
             tube cancer.

          4. Platinum resistant or refractory disease as defined by progression of disease on a
             platinum-containing regimen or recurrence of disease within 180 days of previous
             platinum treatment.

          5. Have measurable disease based on RECIST 1.1. Measurable disease is defined at least
             two lesions that can be accurately measured in at least one dimension (longest
             dimension to be recorded). Each &quot;target&quot; lesion must be &gt;20 mm when measured by
             conventional techniques, including palpation, plain x-ray, CT, and MRI, or &gt;10 mm when
             measured by spiral CT. PET/CT will be acceptable at baseline if PET/CT was previously
             performed and available. Imaging must be within 4 weeks of starting therapy. The
             target lesion must be distinct from other tumor areas selected for pre-treatment
             biopsies.

          6. Subject must be willing to undergo protocol directed biopsies and blood draw for
             immune profiling.

          7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          8. Life expectancy of &gt;/= 4 months in the attending physician's estimation.

          9. Estimated creatinine clearance &gt; 40 mL/min by the Cockcroft-Gault formula: Creatinine
             CL (mL/min) = [Weight (kg) x (140-Age)]/[72 x serum creatinine (mg/dL)] x 0.85.

         10. WBC &gt;/= 3.0 X 103/ul ; Absolute neutrophil count (ANC) &gt;/= 1.5 x 10^9/L (&gt; 1500 per
             mm^3); Platelet count &gt;/= 100 x 10^9/L (&gt;100,000 per mm^3); Hemoglobin &gt;/= 9.0 g/dL.

         11. Female subjects must either be of non-reproductive potential (i.e., post-menopausal by
             history: &gt;/=60 years old and no menses for &gt; 1 year without an alternative medical
             cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history
             of bilateral oophorectomy) or must have a negative serum pregnancy test upon study
             entry.

         12. Subject must be willing and able to comply with the protocol for the duration of the
             study including undergoing treatment and scheduled visits and examinations including
             follow up.

         13. Signed informed consent for Protocol PA13-0291.

        Exclusion Criteria:

          1. Absence of a biopsiable lesion as determined by Radiologist.

          2. Chemotherapy, hormonal, or biologic treatment for ovarian, fallopian tube, or primary
             peritoneal cancer in the last 21 days.

          3. History of another primary malignancy except for: a. Malignancy treated with curative
             intent and with no known active disease &gt;/=5 years before the first dose of study drug
             and of low potential risk for recurrence; b. adequately treated non-melanoma skin
             cancer or lentigo maligna without evidence of disease; or c. adequately treated
             carcinoma in situ without evidence of disease, e.g. cervical cancer in situ.

          4. Current or prior use of immunosuppressive medication within 21 days before the first
             dose of PD 0360324, with the exceptions of intranasal and inhaled corticosteroids and
             systemic corticosteroids at physiological doses (defined as not exceeding 10 mg/day of
             prednisone, or an equivalent dose of over corticosteroid).

          5. Prior Immunotherapy with immune checkpoint inhibitors.

          6. Any unresolved toxicity (&gt;CTCAE grade 1) from previous anti-cancer therapy with the
             exception of alopecia. Subjects with irreversible toxicity that is not reasonably
             expected to be exacerbated by the investigational product may be included (e.g.,
             hearing loss, peripheral neuropathy).

          7. Subjects with an active infection requiring antibiotics or at an increased risk of
             latent infection that may affect safe study participation.

          8. Subjects with existing periorbital edema.

          9. Subjects with aspartate aminotransferase (AST) or alanine transaminase (ALT) &gt;/= 2x
             ULN.

         10. Subjects with creatine kinase &gt; ULN.

         11. Subjects with clinically significant active ischemic heart disease, cardiac muscle
             disease (including cardiomyopathy or congestive heart failure) or myodegenerative
             disorders that may affect safe study participation.

         12. Receipt of live attenuated vaccination within 30 days prior to study entry or within
             30 days prior to study entry.

         13. History of allergic or anaphylactic reaction to any therapeutic or diagnostic
             monoclonal antibody (IgG protein) or molecules made of components of monoclonal
             antibodies (e.g., Enbrel which is the Fc portion of an antibody or Lucentis which is a
             Fab).

         14. Pregnant or breastfeeding women or women of child-bearing potential who are not
             willing to use two highly effective methods of contraception (i.e., a hormonal
             contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide,
             or abstinence).

         15. Uncontrolled intercurrent illness including, but not limited to, bowel obstruction,
             uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic
             ulcer disease or gastritis, active bleeding diatheses including any subject known to
             have evidence of acute or chronic hepatitis B, hepatitis C or human immunodeficiency
             virus (HIV), tuberculosis, or psychiatric illness/social situations that would limit
             compliance with study requirements or compromise the ability of the subject to give
             written informed consent, or undergo study procedures.

         16. History of leptomeningeal carcinomatosis or brain metastasis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amir A. Jazaeri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amir A. Jazaeri, MD</last_name>
    <phone>713-745-1613</phone>
    <email>CR_Study_Registration@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2016</study_first_submitted>
  <study_first_submitted_qc>October 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2016</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Malignant Neoplasm of Female Genital Organs</keyword>
  <keyword>Epithelial ovarian cancer</keyword>
  <keyword>Fallopian tube cancer</keyword>
  <keyword>Primary peritoneal cancer</keyword>
  <keyword>PD 0360324</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Cytoxan</keyword>
  <keyword>Neosar</keyword>
  <keyword>Pharmacokinetic testing</keyword>
  <keyword>PK</keyword>
  <keyword>Pharmacodynamic testing</keyword>
  <keyword>PD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
    <mesh_term>Genital Neoplasms, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

